RE:RE:RE:RE:RE:KWSdeluxe --care to elaborate on your price prediction???That is not my understanding. Look at the ONC Website that was updated March 5th, 2021.
https://ir.oncolyticsbiotech.com/press-releases/detail/529/oncolytics-biotech-reports-fourth-quarter-and-full-year
It states
- Strong financial foundation with approximately $50 million in cash on hand and cash runway to H2 2022
They just sold a bunch of shares through the previous share sale agreement. So, they are good cash wise for a while. No need to do another financing at this time. They definitely will need more cash to go into a Phase III Trial or Partnership or Buyout. But that is a while away.
Both Pfiezer's and Mereck's CEOs have openly stated that they are looking to buy imuno companies that are best-in-class and first-in-class and that are Phase III ready, as they want to run the Phase III trials the way that they want. They have also stated that they known that these companies are going to be expensive to buy, but are prepared to pay top dollar for them to get what they want.
ONC/ONCY is best-in-class and first-in-class with 2 biomarkers and systemic administration. There is nothing else out there like it right now.
Based on that, I really do not see ONC/ONCY running the Phase III trial. They will be bought out IMO.
I am still expecting Roche to step up first, as they are the furthest along with combination therapy data with Tecentriq. They are quiet and have been shutting down other so-so cancer trials, IMHO clearing house for a big purchase. Only time will tell.
I also see that they have moved the AWARE-1 Final results back to H2 of 2021.